
白念珠菌的形态发生与致病性
Candida albicans morphological plasticity and pathogenesis
白念珠菌是一种广泛存在于人体内的共生真菌,也是人类最常见的机会性致病真菌,可引起浅表感染甚至威胁生命的系统性感染。白念珠菌具有很强的形态可塑性,而且这种形态可塑性与致病性密切相关。白念珠菌在侵染的过程中可以进行酵母、假菌丝和真菌丝之间的形态转换。除此之外,white形态、opaque形态、gray形态和GUT细胞在宿主不同的部位具有生长繁殖优势。本文总结了白念珠菌各种形态特征以及它们与致病性之间的联系,同时我们也简述了宿主环境因素调控这些形态的发生与转换的机理。
Candida albicans is a ubiquitous commensal of the mammalian microbiome and the most prevalent fungal pathogen of humans. It can cause superficial infections of the oropharynx, vagina, skin, and nails. In susceptible patients, C. albicans can enter the bloodstream and cause a frequently fatal disseminated infection. Morphological plasticity is its defining feature and is critical for its pathogenesis. A cell-type transition between yeast and hyphal morphologies in C. albicans was thought to underlie much of the variation in virulence observed in different host tissues. In addition, opaque, gray and gastrointestinally induced transition (GUT) cell types were recently reported that exhibit marked differences in vitro and in animal models of commensalism and disease. In this review, we explore the characteristics of these cell types of C. albicans. We highlight emerging knowledge about the associations of these different morphotypes with different host niches and virulence potential, as well as the environmental cues and signalling pathways that are involved in the morphological transitions.
白念珠菌 / 形态发生 / 菌丝发育 / 白灰转换 / 致病性 {{custom_keyword}} /
Candida albicans / morphogenesis / hyphal development / white-opaque switch / pathogenicity {{custom_keyword}} /
表1 分子对接所使用的受体Table 1 Receptors used for molecular docking |
PDB ID | 缩写 Abbreviation | 名称 Name | 功能 Function |
---|---|---|---|
2XOW | p53 | p53蛋白 p53 protein | 防止癌变,修复缺陷 Prevent cancer and repair defects |
IYSI | Bcl-xl | 抗凋亡蛋白 Anti-apoptotic proteins | 阻止凋亡 Prevent apoptosis |
5HG5 | EGFR | 表皮生长因子受体 Epidermal growth factor receptor | 加速促进细胞异常生长和分裂,最终导致肿瘤诞生 Accelerate the abnormal growth and division of cells, and eventually lead to the birth of tumors |
1M48 | IL-2 | 白细胞介素-2 Interleukin-2 | 促进淋巴细胞生长、增殖、分化,能诱导和增强细胞毒活性 Promote the growth, proliferation and differentiation of lymphocyte, induce and enhance cytotoxic activity |
1Y6B | VEGFR2 | 血管内皮细胞生长因子受体2 Vascular endothelial growth factor receptor 2 | 调节淋巴管内皮细胞和血管内皮细胞,促进淋巴管和血管的生成,还有调节淋巴细胞的迁移等作用 Regulate lymphatic endothelial cells and vascular endothelial cells, promote the production of lymphatic vessels and blood vessels, and regulate the migration of lymphocytes, etc. |
图1 不同类型羊毛甾烷型三萜化合物的结构通式Fig. 1 General structural formula of lanostane triterpenes with different types. |
表2 灵芝子实体酸性三萜化合物对L1210细胞增殖的抑制作用Table 2 Inhibition of acidic triterpenes from fruiting bodies of Ganoderma lingzhi to L1210 cell proliferation |
灵芝子实体酸性三萜 Acidic triterpenes from fruiting bodies of G. lingzhi | 母环 Female ring | R1 | R2 | R3 | R4 | R5 | R6 | R7 | IC50 (μmol/L) |
---|---|---|---|---|---|---|---|---|---|
Ganoderic acid I | A | β-OH | β-OH | =O | -H | =O | β-OH | =O | 39.54 |
Ganoderic acid ε | A | β-OH | β-OH | =O | -H | =O | -H | β-OH | - |
Ganoderenic acid C | B | β-OH | β-OH | =O | -H | α-OH | =O | - | - |
Ganoderic acid C2 | A | β-OH | β-OH | =O | -H | α-OH | -H | =O | 520.54 |
Ganoderic acid C6 | A | β-OH | =O | =O | β-OH | =O | -H | =O | 2 793.27 |
Ganoderic acid G | A | β-OH | β-OH | =O | β-OH | =O | -H | =O | 58.26 |
Ganoderic acid B | A | β-OH | β-OH | =O | -H | =O | -H | =O | 77.32 |
Ganoderenic acid B | B | β-OH | β-OH | =O | -H | =O | =O | - | 58.81 |
Ganoderenic acid A | B | =O | β-OH | =O | -H | α-OH | =O | - | 351.85 |
Ganoderic acid A | A | =O | β-OH | =O | -H | α-OH | -H | =O | 104.19 |
Ganoderic acid K | A | β-OH | β-OH | =O | β-OAc | =O | -H | =O | 116.97 |
Ganoderenic acid E | B | =O | β-OH | =O | β-OH | =O | =O | 135.46 | |
Ganoderic acid H | A | β-OH | =O | =O | β-OH | =O | -H | =O | 417.07 |
Ganoderenic acid H | B | β-OH | =O | =O | -H | =O | =O | - | 108.75 |
Lucidenic acid A | - | - | - | - | - | - | - | - | 103.41 |
Ganoderic acid N | A | =O | β-OH | =O | -H | =O | -H | =O | - |
Ganoderic acid D | A | =O | β-OH | =O | -H | =O | -H | =O | 3.67 |
Ganoderenic acid D | B | =O | β-OH | =O | -H | =O | =O | 27 094.48 | |
Ganoderic acid Z | C | β-OH | =O | =O | -H | -H | 2 289.44 | ||
Ganoderic acid F | A | =O | =O | =O | β-OAc | =O | -H | =O | 265.35 |
Ganoderenic acid F | B | =O | =O | =O | -H | =O | =O | - | 72.91 |
Ganoderic acid DM | C | =O | =O | -H | -H | -H | - | - | 75.48 |
Ganoderic acid Y | D | β-OH | -H | - | - | - | - | - | - |
Ganoderic acid TN | D | β-OH | β-OAc | - | - | - | - | - | 57.75 |
注:“-”表示在受试浓度下化合物对L1210无作用,下同 | |
Note: “-” indicates that the compound has no effect on L1210 at the tested concentration, the same below. |
表3 灵芝子实体中性三萜化合物对L1210细胞增殖的抑制作用Table 3 Inhibition of neutral triterpenes from fruiting bodies of Ganoderma lingzhi to L1210 cell proliferation |
灵芝子实体中性三萜 Neutral triterpenes from fruiting bodies of G. lingzhi | 母环 Female ring | R1 | R2 | R3 | R4 | IC50 (μmol/L) |
---|---|---|---|---|---|---|
Ganodermanontriol | F | =O | α-OH | -CH2OH | β-OH | 51.05 |
Ganoderiol A | F | β-OH | -OH | -CH2OH | -OH | 30.30 |
Ganodermanondiol | F | =O | α-OH | -CH3 | -OH | 137.38 |
Ganoderiol F | E | =O | -CH2OH | -CH2OH | - | 147.92 |
Ganoderol A | E | =O | -CH3 | -CH2OH | - | 65.21 |
Ganoderal A | E | =O | -CH3 | -CHO | - | 28.44 |
Ganoderol B | E | β-OH | -CH3 | -CH2OH | - | 54.28 |
表4 灵芝菌丝体三萜化合物对L1210细胞增殖的抑制作用Table 4 Inhibition of triterpenes from mycelia of Ganoderma lingzhi to L1210 cell proliferation |
灵芝菌丝体三萜 Mycelial triterpenes | 母环 Female ring | R1 | R2 | R3 | IC50 (μmol/L) |
---|---|---|---|---|---|
Ganoderic acid T | G | α-OAc | α-OAc | β-OAc | 1.92 |
Ganoderic acid S | G | α-OH | -H | β-OAc | 19.33 |
Ganoderic acid P | G | α-OH | α-OAc | β-OAc | 26.66 |
Ganoderic acid T1 | G | α-OAc | α-OAc | β-OH | 21.12 |
Ganoderic acid Mk | G | α-OAc | α-OH | β-OAc | 16.71 |
Ganoderic acid Me | G | α-OAc | α-OAc | -H | 9.66 |
Lanosta-7,9(11),24-trien-3α-hydroxy-26-oic acid | G | α-OH | -H | -H | 29.97 |
Ganoderic acid R | G | α-OAc | -H | β-OAc | 31.69 |
表5 层迭树舌子实体三萜化合物对L1210细胞增殖的抑制作用Table 5 Inhibition of triterpenes from fruiting bodies of Ganoderma lobatum to L1210 cell proliferation |
树舌环氧酸三萜 Applanoxidic acids | 母环 Female ring | R1 | R2 | R3 | R4 | IC50 (μmol/L) |
---|---|---|---|---|---|---|
Applanoxidic acid H | H | β-OH | α-OH | =O | -OH | 10 083.46 |
Applanoxidic acid A | I | =O | =O | α-OH | - | 272.52 |
Applanoxidic acid G | H | =O | =O | β-OH | -OH | 3 477.67 |
Applanoxidic acid C | H | =O | =O | =O | -OH | 1 507.38 |
Applanoxidic acid E | I | =O | =O | β-OH | - | 84.64 |
Applanoxidic acid F | I | =O | =O | =O | - | 166.01 |
表6 配体与靶蛋白对接Table 6 Docking of ligand to target protein |
配体 Ligand | p53 | Bcl-xl | EGFR | IL-2 | VEGFR2 | |||||
---|---|---|---|---|---|---|---|---|---|---|
Poses | Score | Poses | Score | Poses | Score | Poses | Score | Poses | Score | |
Ganoderic acid P | 10 | 115.52 | 10 | 142.42 | 5 | 123.16 | 5 | 118.39 | 10 | 133.25 |
Ganoderma acid T1 | 3 | 106.89 | 10 | 140.52 | 22 | 111.43 | 1 | 102.88 | 10 | 135.49 |
Ganoderic acid S | 6 | 113.64 | 10 | 131.19 | 3 | 119.55 | 10 | 145.95 | 10 | 123.33 |
Ganoderic acid T | 10 | 119.76 | 10 | 152.44 | 4 | 132.70 | 2 | 116.23 | 10 | 126.43 |
Ganoderic acid Me | 10 | 112.97 | 10 | 141.92 | 3 | 105.81 | 10 | 115.93 | 10 | 131.55 |
Ganoderic acid R | 10 | 112.53 | 10 | 142.54 | 2 | 121.23 | 10 | 142.28 | 10 | 125.44 |
Ganoderic acid Mk | 2 | 104.29 | 10 | 136.51 | - | - | 9 | 127.94 | 10 | 127.44 |
Lanosta-7,9(11),24-trien-3α-hydroxy-26-oic acid | 2 | 108.04 | 10 | 129.37 | 2 | 114.60 | 10 | 131.04 | 10 | 118.92 |
Ganoderic acid I | 2 | 113.87 | 10 | 134.51 | - | - | 9 | 119.06 | 5 | 105.76 |
Ganoderic acid D | 2 | 106.48 | 10 | 140.06 | - | - | 10 | 123.40 | 10 | 111.06 |
Ganoderiol A | 1 | 101.96 | 10 | 141.78 | 2 | 122.61 | 10 | 122.90 | 10 | 116.80 |
Ganodera A | 1 | 110.40 | 10 | 129.12 | 3 | 104.15 | 10 | 129.88 | 10 | 107.94 |
注:化合物的众多对接Poses中只给出LibDock打分最高值 | |
Note: Only the highest LibDock score is given among many poses. |
图2 灵芝羊毛甾烷型三萜与靶蛋白分子对接A:Ganoderic acid T与p53蛋白对接;B:Ganoderic acid T与Bcl-xl蛋白对接;C:Ganoderic acid T与EGFR蛋白对接;D:Ganoderic acid S与IL-2蛋白对接;E:Ganoderic acid T1与VEGFR2蛋白对接 Fig. 2 Molecular docking of lanostane triterpenes from Ganoderma spp. to target proteins. A: Docking of ganoderic acid T to p53 protein; B: Docking of ganoderic acid T to Bcl-xl protein; C: Docking of ganoderic acid T to EGFR protein; D: Docking of ganoderic acid S to IL-2 protein; E: Docking of ganoderic acid T1 to VEGFR2 protein. |
[1] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[2] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[3] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[4] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[5] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[6] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[7] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[8] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[9] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[10] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[11] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[12] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[13] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[14] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[15] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[16] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[17] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[18] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[19] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[20] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[21] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[22] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[23] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[24] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[25] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[26] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[27] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[28] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[29] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[30] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[31] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[32] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[33] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[34] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[35] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[36] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[37] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[38] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[39] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[40] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[41] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[42] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[43] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[44] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[45] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[46] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[47] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[48] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[49] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[50] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[51] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[52] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[53] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[54] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[55] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[56] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[57] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[58] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[59] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[60] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[61] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[62] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[63] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[64] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[65] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[66] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[67] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[68] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[69] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[70] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[71] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[72] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[73] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[74] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[75] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
[76] |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
{{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
〈 |
|
〉 |